Market Overview:
The global Antimicrobial Susceptibility Testing Market is estimated to be valued at US$ 3,525.75 million in 2022 and is projected to exhibit a CAGR of 6.4% during the forecast period of 2022 to 2030, according to a new report published by Coherent Market Insights. Antimicrobial susceptibility testing refers to the laboratory process of determining the effectiveness of specific antibiotic treatments against bacterial and fungal infections.
Market Key Trends:
One key trend shaping the Antimicrobial Susceptibility Testing market is the increasing prevalence of antibiotic-resistant infections. With the overuse and misuse of antibiotics, many bacteria and fungi have developed resistance, making it critical to identify effective treatment options. Antimicrobial susceptibility testing allows clinicians to select appropriate antibiotics and optimize patient outcomes.
For instance, studies have shown that multidrug-resistant bacterial infections are on the rise, leading to higher mortality rates and increased healthcare costs. In response to this trend, government initiatives and regulatory guidelines are encouraging the adoption of antimicrobial susceptibility testing in clinical settings.
Porter’s Analysis:
The threat of new entrants:
Low.
The market is dominated by established players with significant investments in research and development. High entry barriers, such as stringent regulatory requirements and the need for advanced technology, limit the entry of new competitors.
Bargaining power of buyers:
Moderate.
While healthcare institutions and laboratories demand accurate and affordable testing solutions, they often rely on established manufacturers due to the critical nature of the testing process. However, buyers have the power to switch suppliers if better solutions become available.
Bargaining power of suppliers:
Moderate.
Suppliers of antimicrobial susceptibility testing equipment and reagents have a moderate level of bargaining power due to the availability of multiple options in the market. However, for niche products or specific technologies, suppliers may hold a stronger position.
The threat of new substitutes:
Low.
Antimicrobial susceptibility testing is a vital component of infection management, and there are no direct substitutes for accurate testing. Alternative methods, such as empirical therapy, may not offer the same precision in selecting appropriate antibiotics.
Competitive rivalry:
High.
The market is highly competitive, with the presence of several key players offering a wide range of testing solutions. Competitive strategies include technological advancements, collaborations, and mergers and acquisitions to strengthen market position.
Key Takeaways:
The global Antimicrobial Susceptibility Testing market is expected to witness high growth, exhibiting a CAGR of 6.4% over the forecast period. The increasing prevalence of antibiotic-resistant infections and the growing awareness among healthcare professionals about the importance of targeted therapies are driving market growth.
Regionally, North America is expected to be the dominant market due to the presence of advanced healthcare infrastructure, significant investments in research and development, and rising incidences of antibiotic-resistant infections. Europe is also anticipated to contribute substantially to market growth.
Key players operating in the global Antimicrobial Susceptibility Testing market include Thermo Fisher Scientific Inc., BIOMÉRIEUX, HiMedia Laboratories, and Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd., Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc., and Zhuhai DL Biotech Co., Ltd. These key players are continuously investing in research and development to introduce advanced testing solutions and gain a competitive edge in the market.
In conclusion, the Antimicrobial Susceptibility Testing market is poised for significant growth driven by the increasing need for effective therapeutic interventions in the face of rising antibiotic resistance. Investment in research and development, along with collaborations and mergers, will play a vital role in shaping the market’s future landscape.